-
Je něco špatně v tomto záznamu ?
Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study
ZK. Kusnirikova, I. Kacirova, V. Pesakova, P. Hradilek, H. Brozmanova, M. Grundmann
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- hydroxybutyráty * MeSH
- krotonáty * MeSH
- lidé MeSH
- nitrily * MeSH
- pilotní projekty MeSH
- prospektivní studie MeSH
- průřezové studie MeSH
- relabující-remitující roztroušená skleróza * farmakoterapie MeSH
- roztroušená skleróza * farmakoterapie MeSH
- toluidiny * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Teriflunomide is administered orally to treat relapsing-remitting multiple sclerosis. In this prospective pilot study, the free and total serum concentrations of teriflunomide obtained during routine health care were measured and their relationship with disease activity was evaluated. METHODS: Eighty-nine patients were included in this study. Blood samples were collected from April 2021 to February 2022, and free and total teriflunomide serum concentrations were measured. Patient assessment involved monitoring of blood counts and potential adverse effects of teriflunomide. RESULTS: In the steady-state group, total teriflunomide concentrations ranged from 14.7 to 144.2 mg/L, while free concentrations from 31.1 to 389.7 μg/L. In the non-steady-state group, the total concentration ranged from 2.2 to 59.3 mg/L, with free concentrations ranging from 6.8 to 143.5 μg/L. In the steady-state group, a significant inverse correlation was found between absolute peripheral blood lymphocyte count and both total and free teriflunomide serum concentrations. CONCLUSION: Although all patients were treated with the same dose, up to a 10-fold difference in total and free teriflunomide serum concentrations, and up to a 5-fold difference in steady-state trough concentrations were observed. This vast interindividual variability can potentially lead to toxicity or, conversely, to suboptimal therapeutic concentrations of teriflunomide, with the risk of further worsening of multiple sclerosis compensation.
Department of Neurology University Hospital Ostrava 17 listopadu 1790 5 Ostrava 70852 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006721
- 003
- CZ-PrNML
- 005
- 20240423155447.0
- 007
- ta
- 008
- 240412e20240201ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jns.2024.122910 $2 doi
- 035 __
- $a (PubMed)38309248
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kusnirikova, Zuzana Krska $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic; Department of Children Neurology, Department of Neurology, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 70852, Czech Republic. Electronic address: zuzana.kusnirikova@fno.cz
- 245 10
- $a Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study / $c ZK. Kusnirikova, I. Kacirova, V. Pesakova, P. Hradilek, H. Brozmanova, M. Grundmann
- 520 9_
- $a BACKGROUND: Teriflunomide is administered orally to treat relapsing-remitting multiple sclerosis. In this prospective pilot study, the free and total serum concentrations of teriflunomide obtained during routine health care were measured and their relationship with disease activity was evaluated. METHODS: Eighty-nine patients were included in this study. Blood samples were collected from April 2021 to February 2022, and free and total teriflunomide serum concentrations were measured. Patient assessment involved monitoring of blood counts and potential adverse effects of teriflunomide. RESULTS: In the steady-state group, total teriflunomide concentrations ranged from 14.7 to 144.2 mg/L, while free concentrations from 31.1 to 389.7 μg/L. In the non-steady-state group, the total concentration ranged from 2.2 to 59.3 mg/L, with free concentrations ranging from 6.8 to 143.5 μg/L. In the steady-state group, a significant inverse correlation was found between absolute peripheral blood lymphocyte count and both total and free teriflunomide serum concentrations. CONCLUSION: Although all patients were treated with the same dose, up to a 10-fold difference in total and free teriflunomide serum concentrations, and up to a 5-fold difference in steady-state trough concentrations were observed. This vast interindividual variability can potentially lead to toxicity or, conversely, to suboptimal therapeutic concentrations of teriflunomide, with the risk of further worsening of multiple sclerosis compensation.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 12
- $a krotonáty $7 D003437
- 650 12
- $a hydroxybutyráty $7 D006885
- 650 12
- $a nitrily $7 D009570
- 650 12
- $a toluidiny $7 D014052
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kacirova, Ivana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 70852, Czech Republic. Electronic address: ivana.kacirova@fno.cz
- 700 1_
- $a Pesakova, Veronika $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 70852, Czech Republic. Electronic address: v.pesakova@fno.cz
- 700 1_
- $a Hradilek, Pavel $u Department of Neurology, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 70852, Czech Republic; Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic. Electronic address: pavel.hradilek@fno.cz
- 700 1_
- $a Brozmanova, Hana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 70852, Czech Republic. Electronic address: hana.brozmanova@fno.cz
- 700 1_
- $a Grundmann, Milan $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 70852, Czech Republic. Electronic address: milan.grundmann@osu.cz
- 773 0_
- $w MED00003004 $t Journal of the neurological sciences $x 1878-5883 $g Roč. 458 (20240201), s. 122910
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38309248 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155444 $b ABA008
- 999 __
- $a ok $b bmc $g 2080988 $s 1216488
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 458 $c - $d 122910 $e 20240201 $i 1878-5883 $m Journal of the neurological sciences $n J Neurol Sci $x MED00003004
- LZP __
- $a Pubmed-20240412
